- Home
- LTRN vs OTLK Comparison
LTRN vs OTLK Comparison
Compare LTRN & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- OTLK
- Stock Information
- Founded
- LTRN 2013
- OTLK 2010
- Country
- LTRN United States
- OTLK United States
- Employees
- LTRN N/A
- OTLK N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LTRN Health Care
- OTLK Health Care
- Exchange
- LTRN Nasdaq
- OTLK Nasdaq
- Market Cap
- LTRN 49.9M
- OTLK 42.8M
- IPO Year
- LTRN 2020
- OTLK 2016
- Fundamental
- Price
- LTRN $3.63
- OTLK $1.21
- Analyst Decision
- LTRN Strong Buy
- OTLK Buy
- Analyst Count
- LTRN 1
- OTLK 5
- Target Price
- LTRN $25.00
- OTLK $5.25
- AVG Volume (30 Days)
- LTRN 120.1K
- OTLK 1.4M
- Earning Date
- LTRN 11-14-2025
- OTLK 08-14-2025
- Dividend Yield
- LTRN N/A
- OTLK N/A
- EPS Growth
- LTRN N/A
- OTLK N/A
- EPS
- LTRN N/A
- OTLK N/A
- Revenue
- LTRN N/A
- OTLK $1,505,322.00
- Revenue This Year
- LTRN N/A
- OTLK N/A
- Revenue Next Year
- LTRN N/A
- OTLK $342.80
- P/E Ratio
- LTRN N/A
- OTLK N/A
- Revenue Growth
- LTRN N/A
- OTLK N/A
- 52 Week Low
- LTRN $2.55
- OTLK $0.79
- 52 Week High
- LTRN $6.12
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- LTRN 38.13
- OTLK 45.22
- Support Level
- LTRN $3.75
- OTLK $1.28
- Resistance Level
- LTRN $4.09
- OTLK $1.31
- Average True Range (ATR)
- LTRN 0.30
- OTLK 0.09
- MACD
- LTRN -0.04
- OTLK -0.01
- Stochastic Oscillator
- LTRN 5.95
- OTLK 0.00
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.